摘要
There is a continuously rising incidence of non-alcoholic fatty liver disease (NAFLD) around the world, which parallels the increasing incidence of metabolic diseases. NAFLD is a range of liver conditions that contains simple non-alcoholic fatty liver and advanced non-alcoholic steatohepatitis. In serious cases, NAFLD may develop into cirrhosis or even liver cancer. NAFLD has an intense relationship with metabolic syndrome, type 2 diabetes mellitus. It is known that gut microbiota, and functional molecules such as adenosine monophosphate-activated protein kinase JNK, and peroxisome proliferator-activated receptors (PPARs) in progressing and treating NAFLD. Traditionally, the conventional and effective therapeutic strategy is lifestyle intervention. Nowadays, new medicines targeting specific molecules, such as farnesoid X receptor, PPARs, and GLP-1 receptor, have been discovered and shown beneficial effects on patients with NAFLD. In this article, we focus on the molecular mechanisms and therapeutic approaches to NAFLD.
学科与关键词
- Therapeutic advances in non-alcoholic fatty liver disease: A microbiota-centered viewChen, Hui-Ting; Huang, Hong-Li; Li, Yong-Qiang; Xu, Hao-Ming; Zhou, Yong-Jian*WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26(16): 1901-1911.被引 30
- Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studiesWang, Guang-Yan; Zhang, Xiao-Yan; Wang, Chun-Jiong; Guan, You-Fei*WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29(1): 75-95.被引 3
- A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPARα) and farnesoid X receptor (FXR)Zhou, Shipeng; You, Huimin; Qiu, Shuting; Yu, Dawei; Bai, Yan; He, Jincan; Cao, Hua; Che, Qishi; Guo, Jiao*; Su, Zhengquan*Biomedicine and Pharmacotherapy, 2022, 154: 113577.被引 16
